



STELLA PHARMA CORPORATION

Company Description

BNCT is one of the cancer treatment methods that combine a neutron irradiation device and a boron-containing drug, which has the advantage to be able to treat once or in one day. It is a new concept of cancer treatment method led by researchers in Japan, among other countries.

Kansai area was unique and suitable for BNCT research because institutes in various fields such as medicine, pharmacy, and physics were close to the Kyoto University Complex Atomic Energy Research Institute, one of the world's leading research center for BNCT clinical studies. Since Stella Chemifa, our parent company that manufactures boron 10, which is essential for BNCT, has been based in Osaka, it was natural to meet BNCT and be involved in its development, and Stella Pharma was established.

Though many pieces of cancer research have conducted, there is no single method that will cure cancer reliably. Currently, multidisciplinary combination therapy with various modalities is commonly conducted.

Stella Pharma has been consistently involved in the practical application of BNCT, a new type of radiotherapy, and played an important role in this multidisciplinary cancer therapy since we started business in Osaka in 2007. In May 2020, we launched the world's first boron-containing drug for BNCT. We believe that we took a new application of BNCT, a new type of radiotherapy, and played an step as a pharmaceutical company and the next stage of BNCT has begun at the same time.

To spread "a tool that will be a new light for people fighting cancer" globally, we will continue to take on challenges. By stably providing high quality drugs, we will strive for a reliable pharmaceutical company.

As a pioneer in the development of boron-containing drug for BNCT, we also recognize that we have a social responsibility for future cancer therapy.

Listed on the Tokyo Stock Exchange Mothers leads us another growth into a company that enables continuous business implementation. Under a sound corporate management system, we will try our best to gain the recognition and social credibility of BNCT and our company itself.

Company Details

Head Office

Japan

Main Business

BNCT (Boron Neutron Capture Therapy ; ホウ素中性子捕捉療法) に用いるホウ素薬剤開発および製造販売

President

上原 幸樹

Established

2007年6月1日

Capital

30億円

URL

<https://stella-pharma.co.jp/>

Offices

Main Office

ORIX Kourabashi Bldg.
3-2-7 Kourabashi, Osaka-shi Chuo-ku
Osaka, Japan, 5410043
